Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort

Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, r...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Current oncology (Toronto) Ročník 31; číslo 3; s. 1656 - 1666
Hlavní autoři:	Nannini, Simon, Guisier, Florian, Curcio, Hubert, Ricordel, Charles, Demontrond, Pierre, Abdallahoui, Safa, Baloglu, Seyyid, Greillier, Laurent, Chouaid, Christos, Schott, Roland
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 01.03.2024 MDPI
Témata:	Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological - therapeutic use Brain brain metastasis Brain Neoplasms Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment central nervous system Development and progression Humans immunotherapy Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Metastasis non-small cell lung cancer Patient outcomes Pharmaceutical industry Radiotherapy real-life data Retrospective Studies France United States non-small cell lung cancer brain metastasis real-life data immunotherapy central nervous system
ISSN:	1718-7729, 1198-0052, 1718-7729
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.
AbstractList	Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM. Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25/31). Among 38/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.
Audience	Academic
Author	Curcio, Hubert Nannini, Simon Ricordel, Charles Greillier, Laurent Demontrond, Pierre Schott, Roland Abdallahoui, Safa Baloglu, Seyyid Guisier, Florian Chouaid, Christos
AuthorAffiliation	1 Department of Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France; s.nannini@icans.eu (S.N.); s.abdallahoui@icans.eu (S.A.) 7 Department of Pneumology, Centre Hospitalier, 94000 Créteil, France 6 Multidisciplinary Oncology and Therapeutic Innovations, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Aix Marseille University, 13015 Marseille, France 4 Department of Pneumology, Centre Hospitalier Universitaire, 35000 Rennes, France 2 Department of Pneumology, UNIROUEN, LITIS Lab QuantIF Team EA4108, CHU Rouen, Normandie University, Rouen and Inserm CIC-CRB 1404, 76000 Rouen, France 3 Department of Pneumology, Centre Régionale de Lutte Contre le Cancer François Baclesse, 14000 Caen, France 5 Department of Radiological, Centre Hospitalier Universitaire de Strasbourg, 67200 Strasbourg, France
AuthorAffiliation_xml	– name: 4 Department of Pneumology, Centre Hospitalier Universitaire, 35000 Rennes, France – name: 7 Department of Pneumology, Centre Hospitalier, 94000 Créteil, France – name: 1 Department of Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France; s.nannini@icans.eu (S.N.); s.abdallahoui@icans.eu (S.A.) – name: 2 Department of Pneumology, UNIROUEN, LITIS Lab QuantIF Team EA4108, CHU Rouen, Normandie University, Rouen and Inserm CIC-CRB 1404, 76000 Rouen, France – name: 5 Department of Radiological, Centre Hospitalier Universitaire de Strasbourg, 67200 Strasbourg, France – name: 3 Department of Pneumology, Centre Régionale de Lutte Contre le Cancer François Baclesse, 14000 Caen, France – name: 6 Multidisciplinary Oncology and Therapeutic Innovations, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Aix Marseille University, 13015 Marseille, France
Author_xml	– sequence: 1 givenname: Simon orcidid: 0000-0003-3097-727X surname: Nannini fullname: Nannini, Simon – sequence: 2 givenname: Florian orcidid: 0000-0002-8166-7303 surname: Guisier fullname: Guisier, Florian – sequence: 3 givenname: Hubert surname: Curcio fullname: Curcio, Hubert – sequence: 4 givenname: Charles surname: Ricordel fullname: Ricordel, Charles – sequence: 5 givenname: Pierre surname: Demontrond fullname: Demontrond, Pierre – sequence: 6 givenname: Safa surname: Abdallahoui fullname: Abdallahoui, Safa – sequence: 7 givenname: Seyyid surname: Baloglu fullname: Baloglu, Seyyid – sequence: 8 givenname: Laurent surname: Greillier fullname: Greillier, Laurent – sequence: 9 givenname: Christos orcidid: 0000-0002-4290-5524 surname: Chouaid fullname: Chouaid, Christos – sequence: 10 givenname: Roland orcidid: 0000-0002-7735-5366 surname: Schott fullname: Schott, Roland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38534959$$D View this record in MEDLINE/PubMed
BookMark	eNp9kt9u0zAYxSM0xP7AA3CDLHHDTUccJ7HNDSpRNyY6VtHtgivLsb-knhK7OM7QeDoeDXcd0woIJYoj55yfjvOdw2TPOgtJ8hKnx4Tw9K0avXdWuY7glKQ4K58kB5hiNqE043uP3veTw2G4TlNCKKXPkn3CCpLzgh8kPy_GoFwPA3INWshgwIYBfTdhhT47O1n2sutQBfExH22LKmkVeCStRh-8NBadQ5BDvCPg0oMMoLfmsAJ0tW5ivICWxrYdoGkb2WgBfe1dZ36MvazfoSn6AsG7YQ0qmBu4I5-PXTAqir1RaBlGfbsJtyHOltWn2dcFOj1ZVKhyK-fD8-RpI7sBXtyvR8nVyeyy-jiZX5yeVdP5RBWEhElJgZQKQ84wA15noKUmuKZ1VueFlJlSNdEaS1LIVBcKY6ozllMmoWyasmbkKDnbcrWT12LtTS_9rXDSiLsN51shfYzdgcBZQRnPi5xHRKrSGpca86YkBWdUURpZ77es9Vj3oO-OKrsd6O4Xa1aidTcCp7zkhONIeHNP8O7bCEMQvRlUHJO04MZBkDjrPMesLKP09VbaypjN2MZFpNrIxZQyluVFiYuoOv6HKl4aeqNi7RoT93cMrx6f4SH872pFAd4KVBzv4KF5kOBUbOor_qpv9NA_PMqEWEq3-Q2m-4_zF2sP-JY
CitedBy_id	crossref_primary_10_1016_j_jtho_2025_02_005 crossref_primary_10_1016_S0007_4551_25_00159_6
Cites_doi	10.1056/NEJMoa1810865 10.1016/j.cllc.2020.10.017 10.1016/S1470-2045(16)30053-5 10.1016/S1470-2045(16)30498-3 10.1634/theoncologist.2016-0419 10.1186/s13046-019-1426-2 10.1016/j.jtho.2021.06.020 10.1056/NEJMoa1801005 10.1016/j.cllc.2018.01.007 10.1200/JCO.2021.39.15_suppl.9091 10.1016/S1470-2045(20)30111-X 10.1200/JCO.20.01255 10.1016/S0959-8049(16)31622-7 10.1093/neuonc/noz246 10.1186/s13014-019-1237-9 10.1056/NEJMoa1606774 10.1038/s41591-023-02392-7 10.1007/s11912-011-0203-y 10.1158/1078-0432.CCR-20-0798 10.1016/j.jtho.2019.02.009 10.1016/j.annonc.2021.07.016 10.1038/s41568-019-0205-x 10.1016/j.jtho.2021.04.014 10.1016/S1470-2045(15)70057-4 10.1038/s41467-020-16164-1 10.1158/2159-8290.CD-18-1489 10.4049/jimmunol.179.2.845 10.1016/j.ejca.2008.10.026 10.1200/JCO.22.02561 10.21037/jtd-2019-rbmlc-06
ContentType	Journal Article
Copyright	COPYRIGHT 2024 MDPI AG 2024 by the authors. 2024
Copyright_xml	– notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. 2024
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.3390/curroncol31030126
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic CrossRef MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1718-7729
EndPage	1666
ExternalDocumentID	oai_doaj_org_article_12578945492840c0b16d19f635987c77 PMC10969391 A788245615 38534959 10_3390_curroncol31030126
Genre	Multicenter Study Journal Article
GeographicLocations	France United States
GeographicLocations_xml	– name: France – name: United States
GroupedDBID	--- 04C 29F 2WC 53G 5GY 5VS 6PF AAWTL AAYXX ABDBF ACGFS ACUHS ADBBV AENEX AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BMSDO CITATION CS3 DIK DU5 E3Z EBD EBS EIHBH EJD ESX F5P GROUPED_DOAJ HYE IAO IHR INH ITC KQ8 MODMG OK1 OVT RNS RPM TR2 TUS CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c533t-67e36c1e4818e9b2edad31b7b2b45aa2ccb3dd1a35a0d5c117d28478ae6ff6b83
IEDL.DBID	DOA
ISICitedReferencesCount	3
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001191571000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1718-7729 1198-0052
IngestDate	Fri Oct 03 12:51:29 EDT 2025 Thu Aug 21 18:35:37 EDT 2025 Thu Jul 10 17:36:46 EDT 2025 Mon Oct 20 22:58:50 EDT 2025 Mon Oct 20 17:06:50 EDT 2025 Mon Jul 21 06:02:50 EDT 2025 Tue Nov 18 21:50:06 EST 2025 Thu Oct 16 04:34:21 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	non-small cell lung cancer brain metastasis real-life data immunotherapy central nervous system
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c533t-67e36c1e4818e9b2edad31b7b2b45aa2ccb3dd1a35a0d5c117d28478ae6ff6b83
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-8166-7303 0000-0002-4290-5524 0000-0003-3097-727X 0000-0002-7735-5366 0000-0001-6399-3562
OpenAccessLink	https://doaj.org/article/12578945492840c0b16d19f635987c77
PMID	38534959
PQID	3003441866
PQPubID	23479
PageCount	11
ParticipantIDs	doaj_primary_oai_doaj_org_article_12578945492840c0b16d19f635987c77 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10969391 proquest_miscellaneous_3003441866 gale_infotracmisc_A788245615 gale_infotracacademiconefile_A788245615 pubmed_primary_38534959 crossref_primary_10_3390_curroncol31030126 crossref_citationtrail_10_3390_curroncol31030126
PublicationCentury	2000
PublicationDate	2024-03-01
PublicationDateYYYYMMDD	2024-03-01
PublicationDate_xml	– month: 03 year: 2024 text: 2024-03-01 day: 01
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland
PublicationTitle	Current oncology (Toronto)
PublicationTitleAlternate	Curr Oncol
PublicationYear	2024
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Sun (ref_27) 2021; 22 Waqar (ref_2) 2018; 19 Luft (ref_6) 2018; 379 Sanmamed (ref_21) 2020; 26 Arvanitis (ref_20) 2020; 20 Abid (ref_9) 2019; 11 Lin (ref_30) 2015; 16 Reck (ref_7) 2016; 375 Brastianos (ref_18) 2023; 29 Guckenberger (ref_10) 2021; 32 Camandaroba (ref_28) 2021; 16 Langer (ref_14) 2016; 17 Fischer (ref_24) 2019; 9 Masson (ref_25) 2007; 179 Rucinska (ref_11) 2021; 13 Powell (ref_13) 2021; 16 Patel (ref_4) 2020; 22 Sperduto (ref_3) 2020; 38 Goldberg (ref_26) 2016; 17 Nishijima (ref_31) 2017; 22 Brastianos (ref_23) 2015; 51 Nayak (ref_1) 2012; 14 Valente (ref_8) 2019; 38 Descourt (ref_17) 2021; 39 Goldberg (ref_15) 2020; 21 Nieder (ref_12) 2019; 14 Gandhi (ref_5) 2018; 378 Nadal (ref_19) 2023; 41 Kim (ref_22) 2020; 11 Eisenhauer (ref_29) 2009; 45 Hendriks (ref_16) 2019; 14
References_xml	– volume: 379 start-page: 2040 year: 2018 ident: ref_6 article-title: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1810865 – volume: 22 start-page: 58 year: 2021 ident: ref_27 article-title: Outcomes in Patients with Non-small-cell Lung Cancer with Brain Metastases Treated with Pembrolizumab-based Therapy publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2020.10.017 – volume: 17 start-page: 976 year: 2016 ident: ref_26 article-title: Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30053-5 – volume: 17 start-page: 1497 year: 2016 ident: ref_14 article-title: Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30498-3 – volume: 22 start-page: 470 year: 2017 ident: ref_31 article-title: Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis publication-title: Oncologist doi: 10.1634/theoncologist.2016-0419 – volume: 38 start-page: 419 year: 2019 ident: ref_8 article-title: Immunotherapy of brain metastases: Breaking a “dogma” publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-019-1426-2 – volume: 11 start-page: e4446 year: 2019 ident: ref_9 article-title: Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier publication-title: Cureus – volume: 16 start-page: 1883 year: 2021 ident: ref_13 article-title: Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: Pooled analysis of KEYNOTE-021, -189, and -407 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.06.020 – volume: 378 start-page: 2078 year: 2018 ident: ref_5 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1801005 – volume: 19 start-page: e373 year: 2018 ident: ref_2 article-title: Non-small-cell lung cancer with brain metastasis at presentation publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2018.01.007 – volume: 39 start-page: 9091 year: 2021 ident: ref_17 article-title: First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.15_suppl.9091 – volume: 21 start-page: 655 year: 2020 ident: ref_15 article-title: Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30111-X – volume: 38 start-page: 3773 year: 2020 ident: ref_3 article-title: Survival in patients with brain metastases: Summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient publication-title: J. Clin. Oncol. doi: 10.1200/JCO.20.01255 – volume: 51 start-page: S586 year: 2015 ident: ref_23 article-title: 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets publication-title: Eur. J. Cancer doi: 10.1016/S0959-8049(16)31622-7 – volume: 22 start-page: 577 year: 2020 ident: ref_4 article-title: Exclusion of patients with brain metastases from cancer clinical trials publication-title: Neuro Oncol. doi: 10.1093/neuonc/noz246 – volume: 14 start-page: 33 year: 2019 ident: ref_12 article-title: Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: Multi-national radiation treatment recommendations are heterogeneous publication-title: Radiat. Oncol. doi: 10.1186/s13014-019-1237-9 – volume: 375 start-page: 1823 year: 2016 ident: ref_7 article-title: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606774 – volume: 29 start-page: 1728 year: 2023 ident: ref_18 article-title: Pembrolizumab in brain metastases of diverse histologies: Phase 2 trial results publication-title: Nat. Med. doi: 10.1038/s41591-023-02392-7 – volume: 14 start-page: 48 year: 2012 ident: ref_1 article-title: Epidemiology of brain metastases publication-title: Curr. Oncol. Rep. doi: 10.1007/s11912-011-0203-y – volume: 26 start-page: 4186 year: 2020 ident: ref_21 article-title: PD-1/PD-L1 blockers in NSCLC brain metastases: Challenging paradigms and clinical practice publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0798 – volume: 14 start-page: 1244 year: 2019 ident: ref_16 article-title: Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2019.02.009 – volume: 32 start-page: 1332 year: 2021 ident: ref_10 article-title: EANO–ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2021.07.016 – volume: 20 start-page: 26 year: 2020 ident: ref_20 article-title: The blood-brain barrier and blood-tumour barrier in brain tumours and metastases publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0205-x – volume: 16 start-page: 1379 year: 2021 ident: ref_28 article-title: Immunotherapy as Single Treatment for Patients with NSCLC with Brain Metastases: A Systematic Review and Meta-Analysis—The META-L-BRAIN Study publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.04.014 – volume: 16 start-page: e270 year: 2015 ident: ref_30 article-title: Response assessment criteria for brain metastases: Proposal from the RANO group publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)70057-4 – volume: 11 start-page: 2285 year: 2020 ident: ref_22 article-title: Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma publication-title: Nat. Commun. doi: 10.1038/s41467-020-16164-1 – volume: 9 start-page: 628 year: 2019 ident: ref_24 article-title: Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1489 – volume: 179 start-page: 845 year: 2007 ident: ref_25 article-title: Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.179.2.845 – volume: 45 start-page: 228 year: 2009 ident: ref_29 article-title: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 41 start-page: 4478 year: 2023 ident: ref_19 article-title: Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.22.02561 – volume: 13 start-page: 3246 year: 2021 ident: ref_11 article-title: WBRT for brain metastases from non-small cell lung cancer: For whom and when?-Contemporary point of view publication-title: J. Thorac. Dis. doi: 10.21037/jtd-2019-rbmlc-06
SSID	ssj0033777
Score	2.345671
Snippet	Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central...
SourceID	doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	1656
SubjectTerms	Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological - therapeutic use Brain brain metastasis Brain Neoplasms Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment central nervous system Development and progression Humans immunotherapy Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Metastasis non-small cell lung cancer Patient outcomes Pharmaceutical industry Radiotherapy real-life data Retrospective Studies
Title	Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
URI	https://www.ncbi.nlm.nih.gov/pubmed/38534959 https://www.proquest.com/docview/3003441866 https://pubmed.ncbi.nlm.nih.gov/PMC10969391 https://doaj.org/article/12578945492840c0b16d19f635987c77
Volume	31
WOSCitedRecordID	wos001191571000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 1718-7729 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0033777 issn: 1718-7729 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBdbGWMvY9_11hUNBoOBaWTZlr23NDTbQ5uFpR15M5Is00BiF38Uur9uf9ruJCfEFLaXvZhgyULSnXS_i3S_I-QjhuWBl6F8EwTGRxPgSwW_wNqYNCpUEtoT_J_nYjZLlst0vpfqC--EOXpgN3EnDHUqDZFIDHwRPVIszllaxMg8J7SwceSAerbOlNuDORfCpVXBALJRFLjzTA4O_onu6roqYZZthi2GrAp7FskS99_fnvfs0_Du5J4xmj4jT3sUSceu98_JA1O-II8v-nPyl-T3964FVTINrQo6d9SpDcX_XOmsKv3FRq7XdGLgcQ6LnU5Q9DWVZU5PMWUEvTCtBNjYQAOXiCpN7j4GtEivbgokPaALMHprQ8cYm0XnZqMw_8-vbiPVFzqmP0xbV9swTtuyDfW141lpitcX77Bz2OLZAmmS5_TrdD6hk-oaPIJX5Gp6djn55ve5GnwNgLH1Y2F4rJkJAQCYFKSdy5wzJVSgwkjKQGvF85xJHslRHmnGRI6GMZEmLopYJfw1OSir0hwSGkADRaFEoooUwFqqkiTMZcR0EgVFEHGPjLbyynRPZI75NNYZODQo4uyeiD3yeffJjWPx-FvlU1SCXUUk4LYvQC2zXi2zf6mlRz6hCmW4TUDntOyjHWCISLiVjQW4NgheI48cDWrC8taD4g9bJcywCO_ElabqmoxbukYkLPTIG6eUuz5zQGHg-qYeSQbqOhjUsKRcXVt2cQZObcpT9vZ_TMM78iQAFOgu7R2Rg7buzHvySN-2q6Y-Jg_FMjm2K_cPrPtFzw
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outcomes+of+Patients+with+Non-Small+Cell+Lung+Cancer+and+Brain+Metastases+Treated+with+the+Upfront+Single+Agent+Pembrolizumab%3A+A+Retrospective+and+Multicentric+Study+of+the+ESCKEYP+GFPC+Cohort&rft.jtitle=Current+oncology+%28Toronto%29&rft.au=Nannini%2C+Simon&rft.au=Guisier%2C+Florian&rft.au=Curcio%2C+Hubert&rft.au=Ricordel%2C+Charles&rft.date=2024-03-01&rft.eissn=1718-7729&rft.volume=31&rft.issue=3&rft.spage=1656&rft_id=info:doi/10.3390%2Fcurroncol31030126&rft_id=info%3Apmid%2F38534959&rft.externalDocID=38534959
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1718-7729&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1718-7729&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1718-7729&client=summon